Anavex to Initiate Pre-Clinical Studies in ALS Models

Mutations in Sigma-1 receptor (S1R), a membrane protein involved in preventing protein aggregation in the endoplasmic reticulum, have been implicated in juvenile forms of ALS (see August 2011 story). An agonist to the receptor, developed by Anavex Life Sciences to treat Alzheimer’s disease, has now been shown to protect motor neurons from apoptosis, attenuate ALS progression and extend survival in mutant SOD1-G93A mice. Anavex is now planning to initiate preclinical studies of this S1R agonist in ALS models as a potential therapeutic for ALS.

Mutations in Sigma-1 receptor (S1R), a membrane protein involved in preventing protein aggregation in the endoplasmic reticulum, have been implicated in juvenile forms of ALS (see August 2011 story). An agonist to the receptor, developed by Anavex Life Sciences to treat Alzheimer’s disease, has now been shown to protect motor neurons from apoptosis, attenuate ALS progression and extend survival in mutant SOD1-G93A mice. Anavex is now planning to initiate preclinical studies of this S1R agonist in ALS models as a potential therapeutic for ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail